{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T02:59:13Z","timestamp":1769914753614,"version":"3.49.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,11,19]],"date-time":"2018-11-19T00:00:00Z","timestamp":1542585600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12885-018-5087-x","type":"journal-article","created":{"date-parts":[[2018,11,19]],"date-time":"2018-11-19T13:48:24Z","timestamp":1542635304000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["NUT carcinoma of the nasal cavity that responded to a chemotherapy regimen for Ewing\u2019s sarcoma family of tumors: a case report"],"prefix":"10.1186","volume":"18","author":[{"given":"Kohei","family":"Arimizu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gen","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chinatsu","family":"Makiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mioko","family":"Matsuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takakazu","family":"Sasaguri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akitaka","family":"Makiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,11,19]]},"reference":[{"issue":"1","key":"5087_CR1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s12105-010-0235-x","volume":"5","author":"EB Stelow","year":"2011","unstructured":"Stelow EB, et al. A review of NUT midline carcinoma. Head and Neck Pathol. 2011;5(1):31\u20135.","journal-title":"Head and Neck Pathol"},{"issue":"7","key":"5087_CR2","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1097\/PAS.0b013e318198d666","volume":"33","author":"H Haack","year":"2009","unstructured":"Haack H, et al. Diagnosis of NUT midline carcinoma using a NUT-specific monoclonal antibody. Am J Surg Pathol. 2009;33(7):984\u201391.","journal-title":"Am J Surg Pathol"},{"key":"5087_CR3","doi-asserted-by":"publisher","first-page":"5773","DOI":"10.1158\/1078-0432.CCR-12-1153","volume":"18","author":"DE Bauer","year":"2012","unstructured":"Bauer DE, et al. Clinicopathologic features and long-term outcomes of NUT midline carcinoma. Clin Cancer Res. 2012;18:5773\u20139.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"5087_CR4","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1056\/NEJMoa020890","volume":"348","author":"HE Grier","year":"2003","unstructured":"Grier HE, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med. 2003;348(8):694\u2013701.","journal-title":"N Engl J Med"},{"issue":"7","key":"5087_CR5","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1002\/pbc.20755","volume":"49","author":"F Mertens","year":"2007","unstructured":"Mertens F, et al. Successful treatment of a child with t (15,19)-positive tumor. Pediatr Blood Cancer. 2007;49(7):1015\u20137.","journal-title":"Pediatr Blood Cancer"},{"issue":"12","key":"5087_CR6","first-page":"3327","volume":"51","author":"I Kubonishi","year":"1991","unstructured":"Kubonishi I, et al. Novel t (15,19) (q15; p13) chromosome abnormality in a thymic carcinoma. Cancer Res. 1991;51(12):3327\u20138.","journal-title":"Cancer Res"},{"issue":"2","key":"5087_CR7","first-page":"304","volume":"63","author":"CA French","year":"2003","unstructured":"French CA, et al. BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma. Cancer Res. 2003;63(2):304\u20137.","journal-title":"Cancer Res"},{"issue":"3","key":"5087_CR8","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1111\/his.13368","volume":"72","author":"D Sirohi","year":"2018","unstructured":"Sirohi D, et al. Renal NUT carcinoma: a case report. Histopathology. 2018;72(3):528\u201330.","journal-title":"Histopathology"},{"issue":"3","key":"5087_CR9","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s00428-017-2116-0","volume":"472","author":"LDR Thompson","year":"2018","unstructured":"Thompson LDR, et al. New tumor entities in the 4th edition of the World Health Organization classification of head and neck tumors: nasal cavity, paranasal sinuses and skull base. Virchows Arch. 2018;472(3):315\u201330.","journal-title":"Virchows Arch"},{"issue":"4","key":"5087_CR10","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1080\/08880018.2017.1363839","volume":"34","author":"S Storck","year":"2017","unstructured":"Storck S, et al. Pediatric NUT-midline carcinoma: therapeutic success employing a sarcoma based multimodal approach. Pediatr Hematol Oncol. 2017;34(4):231\u20137.","journal-title":"Pediatr Hematol Oncol"},{"issue":"8","key":"5087_CR11","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1158\/2159-8290.CD-14-0014","volume":"4","author":"CA French","year":"2014","unstructured":"French CA, et al. NSD3-NUT fusion oncoprotein in NUT midline carcinoma: implications for a novel oncogenic mechanism. Cancer Discov. 2014;4(8):928\u201341.","journal-title":"Cancer Discov."},{"issue":"14","key":"5087_CR12","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1101\/gad.267583.115","volume":"29","author":"AA Alekseyenko","year":"2015","unstructured":"Alekseyenko AA, et al. The oncogenic BRD4-NUT chromatin regulator drives aberrant transcription within large topological domains. Genes Dev. 2015;29(14):1507\u201323.","journal-title":"Genes Dev"},{"issue":"3","key":"5087_CR13","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1097\/00000478-200003000-00010","volume":"24","author":"M Gu","year":"2000","unstructured":"Gu M, et al. Cytokeratin immunoreactivity in Ewing's sarcoma: prevalence in 50 cases confirmed by molecular diagnostic studies. Am J Surg Pathol. 2000;24(3):410\u20136.","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"5087_CR14","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.prp.2014.07.006","volume":"211","author":"H Nakamura","year":"2015","unstructured":"Nakamura H, et al. NUT midline carcinoma of the mediastinum showing two types of poorly differentiated tumor cells: a case report and a literature review. Pathol Res Pract. 2015;211(1):92\u20138.","journal-title":"Pathol Res Pract"},{"issue":"7","key":"5087_CR15","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/S0959-8049(00)00028-9","volume":"36","author":"I Elomaa","year":"2000","unstructured":"Elomaa I, et al. Five-year results in Ewing's sarcoma. The Scandinavian sarcoma group experience with the SSGIX protocol. Eur J Cancer. 2000;36(7):875\u201380.","journal-title":"Eur J Cancer"},{"issue":"7","key":"5087_CR16","volume":"7","author":"F Shaikh","year":"2015","unstructured":"Shaikh F, et al. Sinonasal NUT-Midline Carcinoma - A Multimodality Approach to Diagnosis, Staging and Post-Surgical Restaging. Cureus. 2015;7(7):e288.","journal-title":"Cureus."},{"issue":"3","key":"5087_CR17","doi-asserted-by":"publisher","first-page":"247","DOI":"10.4103\/1450-1147.207284","volume":"16","author":"C Perkins","year":"2017","unstructured":"Perkins C, et al. Nuclear protein in testis midline carcinoma presenting in an infant as a pericardial mass with staging by 18F-Fluorodeoxyglucose-positron emission tomography\/computed tomography. World J Nucl Med. 2017;16(3):247\u201350.","journal-title":"World J Nucl Med"},{"issue":"5","key":"5087_CR18","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1158\/2159-8290.CD-15-1335","volume":"6","author":"A Stathins","year":"2016","unstructured":"Stathins A, et al. Clinical response of carcinomas harboring the BRD4-NUT Oncoprotein to the targeted Bromodomain inhibitor OTX015\/MK-8628. Cancer Discov. 2016;6(5):492\u2013500.","journal-title":"Cancer Discov"},{"issue":"7","key":"5087_CR19","doi-asserted-by":"publisher","first-page":"2686","DOI":"10.1158\/0008-5472.CAN-10-3513","volume":"71","author":"BE Schwartz","year":"2011","unstructured":"Schwartz BE, et al. Differentiation of NUT midline carcinoma by epigenomic reprogramming. Cancer Res. 2011;71(7):2686\u201396.","journal-title":"Cancer Res"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-5087-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-018-5087-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-5087-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T00:12:43Z","timestamp":1574122363000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-018-5087-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,19]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["5087"],"URL":"https:\/\/doi.org\/10.1186\/s12885-018-5087-x","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,19]]},"assertion":[{"value":"2 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for publication of their clinical details and clinical images was obtained from his wife of the patient. A copy of the written consent is available by the editor of the journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"1134"}}